REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Eligibility criteria
Qualifiers
Histologically confirmed HCC, intrahepatic cholangiocarcinoma, or metastatic cancer. In the case of suspected HCC in patients with known cirrhosis, noninvasive criteria recommended by the European Association for the Study of Liver Diseases (lesion > 1 cm with arterial phase hyperenhancement and venous phase washout) or LI-RADS score of 5 may be used
≥ 18 years old at time of study enrollment
Child-Pugh A status
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
Disqualifiers
Prior treatment with radioembolization
Cytotoxic chemotherapy or investigational agent within 1 week of SABR
Prior radiotherapy overlapping with study treatment site
Female patients who are pregnant
Trial design
Treatments tested in this trial
- MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Treatment groups
62 Participants
are divided into 1 treatment groupLocations
1Stanford University94304, Palo AltoCalifornia, United States
Sponsors and collaborators
Stanford University
Lead sponsor
Viewray Inc.
Collaborator
Source ClinicalTrials.gov